Related Experiment Videos
[Experiences with clofazimine therapy of Melkersson-Rosenthal syndrome]
1Dermatologische Klinik und Poliklinik, Medizinischen Fakultät (Charité) Humboldt-Universität zu Berlin.
Abstract:
Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial paralysis, facial oedema, and lingua plicata in association with other symptoms, such as headache and mental changes. Because the origin of this syndrome is still unknown, only symptomatic treatment is possible. In 18 patients suffering from MRS, whether with a complete or with an incomplete picture, we used the antileprosy drug clofazimine for therapy. A decrease in the frequency and intensity of oedema was achieved by this therapy in 94% of patients. However, improvement persisting throughout a follow-up period of up to 3 years was seen in only 62% of patients. We demonstrate that clofazimine is an alternative to glucocorticosteroids for the treatment of MRS.
Insights
Clofazimine, an antileprosy drug, effectively reduced facial swelling in Melkersson-Rosenthal syndrome (MRS) patients. This treatment offers a promising alternative to traditional therapies for managing MRS symptoms.
Area of Science:
- Neurology
- Dermatology
Context:
- Melkersson-Rosenthal syndrome (MRS) is a rare neurological disorder characterized by facial paralysis, edema, and fissured tongue.
- The etiology of MRS remains unknown, necessitating symptomatic treatment approaches.
Purpose:
- To evaluate the efficacy of clofazimine, an antileprosy medication, in treating patients diagnosed with Melkersson-Rosenthal syndrome.
- To compare clofazimine's effectiveness against existing treatment options for MRS.
Summary:
- The study involved 18 patients with complete or incomplete Melkersson-Rosenthal syndrome treated with clofazimine.
- A significant reduction in the frequency and intensity of facial edema was observed in 94% of patients.
- Sustained improvement for up to three years was noted in 62% of patients, indicating long-term benefits.
Impact:
- Clofazimine presents a viable therapeutic alternative to glucocorticosteroids for managing Melkersson-Rosenthal syndrome.
- This finding may lead to improved treatment strategies and patient outcomes for individuals with MRS.